189 related articles for article (PubMed ID: 36106379)
1. Time to exceed pre-randomization monthly seizure count for perampanel in participants with primary generalized tonic-clonic seizures: A potential clinical end point.
Kerr WT; Brandt C; Ngo LY; Patten A; Cheng JY; Kramer L; French JA
Epilepsia; 2022 Nov; 63(11):2994-3004. PubMed ID: 36106379
[TBL] [Abstract][Full Text] [Related]
2. Perampanel for tonic-clonic seizures in idiopathic generalized epilepsy A randomized trial.
French JA; Krauss GL; Wechsler RT; Wang XF; DiVentura B; Brandt C; Trinka E; O'Brien TJ; Laurenza A; Patten A; Bibbiani F
Neurology; 2015 Sep; 85(11):950-7. PubMed ID: 26296511
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
Piña-Garza JE; Rosenfeld W; Saeki K; Villanueva V; Yoshinaga H; Patten A; Williams B; Malhotra M
Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
[TBL] [Abstract][Full Text] [Related]
4. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
Trevathan E; Kerls SP; Hammer AE; Vuong A; Messenheimer JA
Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of adjunctive perampanel in patients with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of Phase II and Phase III double-blind and open-label extension studies in India.
Mehndiratta MM; Gulhane M; Jabeen SA; Patten A; Dash A; Malhotra M
Epilepsia Open; 2021 Mar; 6(1):90-101. PubMed ID: 33681652
[TBL] [Abstract][Full Text] [Related]
6. Time to prerandomization seizure count design sufficiently assessed the safety and tolerability of perampanel for the treatment of primary generalized tonic-clonic seizures.
Kerr WT; Ngo LY; Zhu L; Patten A; Cheng JY; Reddy AS; French JA
Epilepsia; 2024 Jun; ():. PubMed ID: 38864472
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
Nishida T; Lee SK; Wu T; Tiamkao S; Dash A
Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
French JA; Krauss GL; Steinhoff BJ; Squillacote D; Yang H; Kumar D; Laurenza A
Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, safety, and tolerability of adjunctive perampanel in patients from China with focal seizures or generalized tonic-clonic seizures: Post hoc analysis of phase III double-blind and open-label extension studies.
Weiping L; Dong Z; Zhen H; Patten A; Dash A; Malhotra M
CNS Neurosci Ther; 2021 Mar; 27(3):330-340. PubMed ID: 33340263
[TBL] [Abstract][Full Text] [Related]
10. Time to prerandomization monthly seizure count in perampanel trials: A novel epilepsy endpoint.
French JA; Gil-Nagel A; Malerba S; Kramer L; Kumar D; Bagiella E
Neurology; 2015 May; 84(20):2014-20. PubMed ID: 25878175
[TBL] [Abstract][Full Text] [Related]
11. Perampanel as monotherapy and adjunctive therapy for focal onset seizures, focal to bilateral tonic-clonic seizures and as adjunctive therapy of generalized onset tonic-clonic seizures.
Tyrlikova I; Brazdil M; Rektor I; Tyrlik M
Expert Rev Neurother; 2019 Jan; 19(1):5-16. PubMed ID: 30560703
[No Abstract] [Full Text] [Related]
12. Open-label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic-clonic seizures.
Fogarasi A; Flamini R; Milh M; Phillips S; Yoshitomi S; Patten A; Takase T; Laurenza A; Ngo LY
Epilepsia; 2020 Jan; 61(1):125-137. PubMed ID: 31912493
[TBL] [Abstract][Full Text] [Related]
13. Adjunctive perampanel and myoclonic and absence seizures: Post hoc analysis of data from study 332 in patients with idiopathic generalized epilepsy.
Brandt C; Wechsler RT; O'Brien TJ; Patten A; Malhotra M; Ngo LY; Steinhoff BJ
Seizure; 2020 Aug; 80():115-123. PubMed ID: 32563171
[TBL] [Abstract][Full Text] [Related]
14. Long-term open-label perampanel: Generalized tonic-clonic seizures in idiopathic generalized epilepsy.
French JA; Wechsler RT; Trinka E; Brandt C; O'Brien TJ; Patten A; Salah A; Malhotra M
Epilepsia Open; 2022 Sep; 7(3):393-405. PubMed ID: 35445567
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
Steinhoff BJ; Ben-Menachem E; Ryvlin P; Shorvon S; Kramer L; Satlin A; Squillacote D; Yang H; Zhu J; Laurenza A
Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
[TBL] [Abstract][Full Text] [Related]
16. Adjunctive perampanel in partial-onset seizures: Asia-Pacific, randomized phase III study.
Nishida T; Lee SK; Inoue Y; Saeki K; Ishikawa K; Kaneko S
Acta Neurol Scand; 2018 Apr; 137(4):392-399. PubMed ID: 29250772
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
Montouris G; Yang H; Williams B; Zhou S; Laurenza A; Fain R
Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of adjunctive perampanel 4 mg/d for the treatment of focal seizures: A pooled post hoc analysis of four randomized, double-blind, phase III studies.
Steinhoff BJ; Patten A; Williams B; Malhotra M
Epilepsia; 2020 Feb; 61(2):278-286. PubMed ID: 31944276
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of perampanel in adolescent patients with drug-resistant partial seizures in three double-blind, placebo-controlled, phase III randomized clinical studies and a combined extension study.
Rosenfeld W; Conry J; Lagae L; Rozentals G; Yang H; Fain R; Williams B; Kumar D; Zhu J; Laurenza A
Eur J Paediatr Neurol; 2015 Jul; 19(4):435-45. PubMed ID: 25823975
[TBL] [Abstract][Full Text] [Related]
20. PERPRISE: A prospective non-interventional study of PERampanel as only adjunctive treatment in patients with PRImary or SEcondarily generalized tonic-clonic seizures: First interim analysis.
Steinhoff BJ; Goldmann T; Kockelmann E; Winter Y;
Epilepsia Open; 2024 Jun; 9(3):926-939. PubMed ID: 38017663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
